3,3’-Di(5,7-dibromoindol-3-il)-indolin-2-on: Sintesis dan Uji Sitotoksik terhadap Sel Kanker Kolon WiDr
Abstrak
Kanker kolon merupakan salah satu penyebab kematian yang menjadi pusat perhatian di dunia, karena hingga saat ini belum ditemukan obat yang spesifik untuk pengobatannya. Oleh sebab itu, penelitian yang bertujuan untuk mensintesis senyawa yang berpotensi sebagai anti kanker baru seperti senyawa turunan 3,3’-di(indol-3-il)indolin-2-on sangat diperlukan. Sintesis dilakukan dengan mereaksikan 5,7-dibromoindol dan isatin dalam metanol dengan katalis asam menghasilkan senyawa 3,3’-di(5,7-dibromoindol-3-il)-indolin-2-on dengan rendemen 48%. 3,3’-Di(5,7-dibromoindol-3-il)-indolin-2-on bersifat sitotoksik terhadap sel kanker kolon WiDr dengan IC50 6,64 μM.
Referensi
2. Astuti P, Alam G, Hartati MS, Sari D, Wahyuono S. Uji sitotoksik senyawa alkaloid dari spons Petrosia sp.: Potensial pengembangan sebagai antikanker. Majalah Farmasi Indonesia. 2005.16(1):58-62.
3. Yoo M, Choi S, Choi KY, Yon GH, Chae JC, Kim D, Zylstra GJ, Kim E. Trisindoline synthesis and anticancer activity. Biochemical and Biophysical Research Communication. 2008.376:96-99.
4. Kamal A, Srikanth YVV, Khan MNA, Shaik TB, Ashraf M. Synthesis of 3,3-diindolyl oxyindoles effi ciently catalysed by FeCl3 and their in vitro evaluation for anticancer activity. Bioorg Med Chem Lett. 2010. 20(17):5229–31.
5. Mustikasari K, Santoso M. Sintesis 3,3’-Di(5-bromo-N-metilindol-3-il)-5-bromoindolin-2-ona dan uji sitotoksisitasnya terhadap sel Vero. Jurnal Ilmiah Berkala Sains dan Terapan Kimia. 2012.6(1):1-10.
6. Meiyanto E, Susidarti RA, Handayani S, Rahmi F. Ekstrak etanolik biji buah pinang (Areca catechu L.) mampu menghambat proliferasi dan memacu apoptosis sel MFC-7. Majalah Farmasi Indonesia. 2008.19(1):12-19.
Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.
This licence applies to Author(s) and Public Reader means that the users mays :
- SHARE:
copy and redistribute the article in any medium or format - ADAPT:
remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication) - ALIKE:
If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original. - NO ADDITIONAL RESTRICTIONS:
You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
It does however mean that when you use it you must:
- ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
You may not:
- NONCOMMERCIAL: You may not use the article for commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.